Vascular Contribution Modulation Therapy represents a novel therapeutic approach targeting the critical but often overlooked vascular contributions to neurodegenerative diseases. This therapy addresses dysfunction in the neurovascular unit, including endothelial cells, pericytes, smooth muscle cells, and the blood-brain barrier (BBB), which play essential roles in maintaining cerebral homeostasis and are frequently compromised in vascular dementia (VaD), cerebral amyloid angiopathy (CAA), and Alzheimer's disease (AD).
The rationale for this approach stems from growing recognition that vascular dysfunction is not merely a comorbidity but a primary driver of neurodegeneration. Approximately 20-30% of dementia cases have significant vascular contributions, and cerebral small vessel disease is present in the majority of AD cases upon neuroimaging.
The neurovascular unit comprises endothelial cells forming the blood-brain barrier, pericytes, astrocyte end-feet, and neurons that communicate to regulate cerebral blood flow and maintain CNS homeostasis. In neurodegenerative diseases, this unit becomes dysfunctional through multiple mechanisms:
In CAA, amyloid-beta (Aβ) deposits preferentially in the walls of leptomeningeal and cortical vessels, leading to:
Vascular dementia results from cerebrovascular disease affecting cognition through:
Pericytes are critical regulators of capillary diameter and cerebral blood flow. Therapeutic approaches include:
Nitric oxide is essential for vasodilation and endothelial function:
Stabilizing the BBB prevents harmful infiltration:
Improving clearance of Aβ and metabolic waste:
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | Targeting vascular contributions that are underrepresented in AD/PD therapeutic pipelines |
| Mechanistic Rationale | 9 | Strong evidence from neuroimaging, biomarker, and postmortem studies |
| Root Cause Coverage | 8 | Addresses early vascular changes that contribute to neurodegeneration |
| Delivery Feasibility | 7 | Small molecules and biologics that can cross或不 cross BBB with delivery strategies |
| Safety Plausibility | 7 | Existing vasodilators and BBB modulators have established safety profiles |
| Combinability | 9 | Complements amyloid/tau, neuroinflammation, and metabolic therapies |
| De-risking Path | 7 | Surrogate endpoints (BBB permeability, CBF measurements) are quantifiable |
| Multi-disease Potential | 9 | High relevance to VaD, CAA, AD, PD, and small vessel disease |
| Patient Impact | 8 | Addresses vascular contributions often missed in disease-modifying approaches |
| Total | 72/100 |
| Disease | Relevance Score | Rationale |
|---|---|---|
| Vascular Dementia (VaD) | 10 | Core mechanism — direct targeting of vascular dysfunction |
| Cerebral Amyloid Angiopathy (CAA) | 10 | Direct removal of vascular Aβ deposits |
| Alzheimer's Disease | 8 | Strong vascular component in most cases |
| Parkinson's Disease | 6 | Contributing vascular dysfunction in some cases |
| ALS | 5 | Vascular contributions in some subclasses |
| FTD | 5 | Vascular FTD variants exist |
| CBS | 6 | Corticobasal vascular contributions |
| MSA | 5 | Some vascular component in pathogenesis |
| Aging | 9 | Vascular aging is fundamental to age-related cognitive decline |
| Risk | Mitigation |
|---|---|
| Insufficient brain penetration | Use focused ultrasound for transient BBB opening if needed |
| Vascular hemorrhage risk (CAA) | Careful patient selection, exclude severe CAA |
| Variable vascular contribution | Use biomarker enrichment |
| Lack of clear mechanism | Combine multiple vascular targets |